Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O94777
UPID:
DPM2_HUMAN
Alternative names:
Dolichol-phosphate mannose synthase subunit 2
Alternative UPACC:
O94777; Q5XKK9; Q6FGH3
Background:
Dolichol phosphate-mannose biosynthesis regulatory protein, also known as Dolichol-phosphate mannose synthase subunit 2, plays a pivotal role in glycoprotein biosynthesis. It regulates the synthesis of dolichol phosphate-mannose, a critical component in the glycosylation process, and is a key player in the glycosylphosphatidylinositol-N-acetylglucosaminyltransferase complex, essential for GPI biosynthesis.
Therapeutic significance:
The protein is linked to Congenital disorder of glycosylation 1U, a multisystem disorder impacting nervous system development, psychomotor retardation, and immunodeficiency, among other symptoms. Understanding the role of Dolichol phosphate-mannose biosynthesis regulatory protein could open doors to potential therapeutic strategies for this congenital disorder.